Haiyong Wang

shandong first medical university and shandong academy of medical sciences

H指数:28

被引数:2,497

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The LDH-H3K18La-Nur77 Axis Potentiates Immune Escape in Small Cell Lung Cancer

LDH-H3K18La-Nur77轴增强小细胞肺癌的免疫逃逸

Advanced Science

IF14.1

2025-06-240

OAAI

The emerging landscape and future perspective of SCLC transformation: From molecular mechanisms to therapeutic strategies

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

IF5.6

2025-03-010

PRE

Huge extramedullary hematopoiesis mass in the posterior mediastinum: a case report

后纵隔巨大髓外造血肿块1例

FRONTIERS IN ONCOLOGY

IF3.3

2024-12-130

OAAI

Patients with Extensive-Stage Small Cell Lung Cancer Harboring Less Than 4 Metastatic Sites May Benefit from Immune Checkpoint Inhibitor Rechallenge by Reshaping Tumor Microenvironment

IMMUNOTARGETS AND THERAPY

IF4.4

2024-10-010

OAAI

The role of FERMT2 in the tumor microenvironment and immunotherapy in pan-cancer using comprehensive single-cell and bulk sequencing

使用全面的单细胞和批量测序，FERMT2在泛癌症的肿瘤微环境和免疫治疗中的作用

HELIYON

IF3.6

2024-05-011

OAAI

Editorial: Epigenetic regulation of autophagy in inflammatory diseases

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-03-053

OAAI

FTO-mediated autophagy inhibition promotes non-small cell lung cancer progression by reducing the stability of SESN2 mRNA

HELIYON

IF3.6

2024-03-011

OAAI

Neoadjuvant chemotherapy remodels the tumor immune microenvironment by increasing activated and cytotoxic T cell, decreasing B cells and macrophages in small cell lung cancer

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2023-09-212

OAAI

Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions

协调智能疗法以实现小细胞肺癌的最佳治疗: 最新进展和未来方向

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2023-07-145

OAAI

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo

COMMUNICATIONS BIOLOGY

IF5.1

2023-06-014

OAAI

Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions

免疫检查点抑制剂在癌症治疗中的抵抗: 当前进展和未来方向

CANCER LETTERS

IF10.1

2023-05-0140

PRE

Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy

增强肿瘤免疫治疗效果的中药活性成分研究

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-03-1020

OAAI

Untargeted metabolomics and lipidomics identified four subtypes of small cell lung cancer

METABOLOMICS

IF3.3

2022-12-276

PRE

Immunomodulatory role of metalloproteinase ADAM17 in tumor development

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-11-1720

OAAI

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor

TP53/KRAS共突变的非小细胞肺癌患者可从PD-L1抑制剂中获益

FUTURE ONCOLOGY

IF2.6

2022-09-066

PRE

Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

IF8.3

2022-09-017

PRE

Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-06-301

OAAI

Recent advances and challenges of bispecific antibodies in solid tumors

hematology oncology

IF13.5

2021-12-1858

OAAI

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma

FRONTIERS IN ONCOLOGY

IF3.3

2021-09-242

OAAI

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2021-09-082

OAAI

Haiyong Wang

个人简介

教育背景

工作经历

荣誉奖项

研究方向